论文部分内容阅读
目的分析275例妊娠合并疟疾患者的临床特征及临床治疗方案、效果。方法以275例妊娠合并疟疾患者为研究对象,分析患者的临床特征、统计不同妊娠分期下及不同产次下患者的发病率。同时,将本组275例患者随机分为观察组138例和对照组137例。对照组患者在常规治疗的基础上行奎宁注射液治疗,观察组患者在常规治疗的基础上行青蒿琥酯粉针治疗,评价2组患者的临床治疗效果。结果本组275例患者中,妊娠中期患者疟疾的发病率高于妊娠早期和妊娠晚期(P<0.05),初产妇患者疟疾的发病率高于产次为2次及以上产妇的发病率(P<0.05)。观察组患者临床治疗的总有效率为96.37%,对照组为95.62%,2组比较,差异无统计学意义(P>0.05)。但治疗后2个月内,观察组患者的复燃率为6.52%,对照组为14.60%,2组比较,差异具有统计学意义(P<0.05)。结论本组275例非洲妊娠合并疟疾患者中,妊娠中期及初产妇的发病率较高,在临床治疗上青蒿琥酯较奎宁治愈率高、复燃率低,可作为首选治疗药物。
Objective To analyze the clinical characteristics and clinical treatment of 275 pregnant women with malaria. Methods A total of 275 pregnant women with malaria in pregnancy were enrolled in this study. The clinical features of the patients were analyzed. The incidence of patients under different pregnancy stages and different births was calculated. At the same time, this group of 275 patients were randomly divided into observation group 138 cases and control group 137 cases. Patients in the control group were treated with quinine injection on the basis of conventional treatment. The patients in the observation group received artesunate powder injection on the basis of routine treatment, and the clinical effects of the two groups were evaluated. Results The incidence of malaria in the second trimester was higher than that in the first trimester and the second trimester (P <0.05). The incidence of malaria in the first trimester was higher than that in the second trimester (P <0.05). The total effective rate of clinical treatment in observation group was 96.37%, while that in control group was 95.62%. There was no significant difference between the two groups (P> 0.05). However, within 2 months after treatment, the rate of relapse was 6.52% in the observation group and 14.60% in the control group. There was significant difference between the two groups (P <0.05). Conclusion 275 pregnant women with malaria in pregnancy in the second trimester and early maternal morbidity is higher in the clinical treatment of artesunate than quinine cure rate, low rate of relapse can be used as the first choice of treatment.